Jeng · JAMA 2026 · narrative review · n=?

Hepatitis B: A Review.

Cited 4 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative clinical review synthesizing disease epidemiology, diagnosis, and management without a systematic search or meta-analysis.

PubMed 42081318 · doi:10.1001/jama.2026.6070 · record verified 2026-08-31

What was done

This was a narrative clinical review synthesizing evidence on hepatitis B virus (HBV) global epidemiology, transmission, diagnostic serology, natural history, prevention strategies, and antiviral therapeutics based on reported literature and guidelines.

What was found

Globally, HBV affects an estimated 254 million individuals, leading to 1.1 million deaths annually and 1.2 million new infections in 2022 (14,000 in the US). Mother-to-child transmission occurs in 70% to 90% of infants born to HBsAg-positive and HBeAg-positive mothers, but vaccination combined with hepatitis B immune globulin within 12 to 24 hours of birth prevents approximately 94% of perinatal infections (reduced to <1% when maternal antiviral therapy is added). Global birth-dose vaccine coverage was 45% in 2024. Chronic infection develops in 90% of infected infants compared with ≤5% of immunocompetent adults. Untreated chronic HBV carries an 8% to 15% 5-year cumulative risk of cirrhosis, and cirrhosis carries an annual hepatocellular carcinoma (HCC) risk of 3% to 5%. Antiviral therapies (pegylated interferon alfa, entecavir, or tenofovir) suppress viral replication and reduce HCC risk by approximately 50%.

Why it matters

The review summarizes current standards of care, emphasizing that birth-dose vaccination combined with maternal antivirals can virtually eliminate perinatal transmission and that long-term antiviral suppression halts progression to cirrhosis and liver cancer.

Limits

This is a narrative review that does not utilize systematic review methodology, formal quality assessment, or meta-analytic pooling. Specific primary study characteristics, sample sizes, and detailed risk-of-bias metrics were not reported in the abstract.

Cited by